Jasper Therapeutics, Inc. (JSPR)

Market Cap	22.84M -49.8%
Revenue (ttm)	n/a
Net Income	-31.77M
EPS	-1.23
Shares Out	33.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	364,608
Open	0.6930
Previous Close	0.7049
Day's Range	0.6534 - 0.7098
52-Week Range	0.3151 - 2.8300
Beta	3.03
Analysts	Buy
Price Target	7.38 (+975.18%)
Earnings Date	Aug 14, 2026

About JSPR

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: JSPR
• Website: https://jaspertx.com

Analyst Summary

According to 6 analysts, the average rating for JSPR stock is "Buy." The 12-month stock price target is $7.38, which is an increase of 975.18% from the latest price.

Price Target

$7.38

(975.18% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 4, 2026

Data Sources Report a data error